Latest Breaking News On - Jamesr porter - Page 1 : comparemela.com
Share this article
Share this article
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced preclinical data supporting advancement of its parallel lead programs in non-small cell lung cancer (NSCLC), including NUV-520 – a potential best-in-class ROS1-selective inhibitor – and NUV-655 – an ALK-selective inhibitor. Data are being presented at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting from April 10-15 in two separate poster presentations. Posters will be archived on the Nuvalent website at www.nuvalent.com.
In addition, Nuvalent announces the appointment of leading medical oncologist Alexander Drilon, M.D., to its Scientific Advisory Board (SAB). Dr. Drilon currently serves as Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK) and brings deep expertise in early-phas
United-statesCambridgeCambridgeshireUnited-kingdomAmericanJamesr-porterJames-porterJoshuac-horanNancye-kohlHenrye-pelishMatthewd-shairAlexander-drilon